Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort
© 2023 Wiley Periodicals LLC..
VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical-genomic features of VEXAS, and tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information. Overall, 13/29 centers performed UBA1 genomic testing locally, including Sanger sequencing (46%), next-generation sequencing (23%), droplet digital polymerase chain reaction (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9.1 g/dL), with macrocytosis. Bone marrow vacuoles were observed in most cases (89%). The most common rheumatologic association was polychondritis (49%). A concomitant myelodysplastic neoplasm/syndrome (MDS) was diagnosed in 71% of patients (n = 28), chiefly exhibiting lower Revised International Prognostic Scoring System risk profiles. Karyotype was normal in all patients, except three MDS cases showing -Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was DNMT3A (n = 10), followed by TET2 (n = 3). At last follow-up, five patients died and two patients progressed to acute leukemia. Longitudinal UBA1 clonal dynamics demonstrated mutational clearance following transplant. We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal UBA1 clonal dynamics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
American journal of hematology - 99(2024), 2 vom: 22. Jan., Seite 254-262 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ajh.27169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365993166 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365993166 | ||
| 003 | DE-627 | ||
| 005 | 20240122232006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.27169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM365993166 | ||
| 035 | |a (NLM)38108611 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gurnari, Carmelo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical-genomic features of VEXAS, and tracked UBA1 longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant. We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information. Overall, 13/29 centers performed UBA1 genomic testing locally, including Sanger sequencing (46%), next-generation sequencing (23%), droplet digital polymerase chain reaction (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9.1 g/dL), with macrocytosis. Bone marrow vacuoles were observed in most cases (89%). The most common rheumatologic association was polychondritis (49%). A concomitant myelodysplastic neoplasm/syndrome (MDS) was diagnosed in 71% of patients (n = 28), chiefly exhibiting lower Revised International Prognostic Scoring System risk profiles. Karyotype was normal in all patients, except three MDS cases showing -Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was DNMT3A (n = 10), followed by TET2 (n = 3). At last follow-up, five patients died and two patients progressed to acute leukemia. Longitudinal UBA1 clonal dynamics demonstrated mutational clearance following transplant. We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal UBA1 clonal dynamics | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Pascale, Maria Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Vitale, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Diral, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Tomelleri, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Galossi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Falconi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Crisafulli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Frassi, Micol |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoli, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardi, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Condorelli, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Morsia, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Poloni, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Crisà, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Caravelli, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Triggianese, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Brussino, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Battipaglia, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Bindoli, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Sfriso, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Caroni, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Dragani, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Mallegni, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Pilo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Firinu, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Curti, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Papayannidis, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Attilio |e verfasserin |4 aut | |
| 700 | 1 | |a Kordasti, Sharham |e verfasserin |4 aut | |
| 700 | 1 | |a Albano, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pane, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Bocchia, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Lugli, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Frigeni, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Dagna, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Greco, Raffaella |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Campochiaro, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Cantarini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Voso, Maria Teresa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 99(2024), 2 vom: 22. Jan., Seite 254-262 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2024 |g number:2 |g day:22 |g month:01 |g pages:254-262 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.27169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2024 |e 2 |b 22 |c 01 |h 254-262 | ||